• Je něco špatně v tomto záznamu ?

Evaluation of Mesenchymal Stem Cell Therapy for Sepsis: A Randomized Controlled Porcine Study

J. Horak, L. Nalos, V. Martinkova, V. Tegl, L. Vistejnova, J. Kuncova, M. Kohoutova, D. Jarkovska, M. Dolejsova, J. Benes, M. Stengl, M. Matejovic

. 2020 ; 11 (-) : 126. [pub] 20200207

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012866

Background: Treatment with mesenchymal stem cells (MSCs) has elicited considerable interest as an adjunctive therapy in sepsis. However, the encouraging effects of experiments with MSC in rodents have not been adequately studied in large-animal models with better relevance to human sepsis. Objectives: Here, we aimed to assess safety and efficacy of bone marrow-derived MSCs in a clinically relevant porcine model of progressive peritonitis-induced sepsis. Methods: Thirty-two anesthetized, mechanically ventilated, and instrumented pigs were randomly assigned into four groups (n = 8 per group): (1) sham-operated group (CONTROL); (2) sham-operated group treated with MSCs (MSC-CONTROL); (3) sepsis group with standard supportive care (SEPSIS); and (4) sepsis group treated with MSCs (MSC-SEPSIS). Peritoneal sepsis was induced by inoculating cultivated autologous feces. MSCs (1 × 106/kg) were administered intravenously at 6 h after sepsis induction. Results: Before, 12, 18, and 24 h after the induction of peritonitis, we measured systemic, regional, and microvascular hemodynamics, multiple-organ functions, mitochondrial energy metabolism, systemic immune-inflammatory response, and oxidative stress. Administration of MSCs in the MSC-CONTROL group did not elicit any measurable acute effects. Treatment of septic animals with MSCs failed to mitigate sepsis-induced hemodynamic alterations or the gradual rise in Sepsis-related organ failure assessment scores. MSCs did not confer any protection against sepsis-mediated cellular myocardial depression and mitochondrial dysfunction. MSCs also failed to modulate the deregulated immune-inflammatory response. Conclusion: Intravenous administration of bone marrow-derived MSCs to healthy animals was well-tolerated. However, in this large-animal, clinically relevant peritonitis-induced sepsis model, MSCs were not capable of reversing any of the sepsis-induced disturbances in multiple biological, organ, and cellular systems.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012866
003      
CZ-PrNML
005      
20210507102247.0
007      
ta
008      
210420s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2020.00126 $2 doi
035    __
$a (PubMed)32117276
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Horak, Jan $u First Medical Department, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia $u Faculty of Medicine in Pilsen, Biomedical Center, Charles University, Pilsen, Czechia
245    10
$a Evaluation of Mesenchymal Stem Cell Therapy for Sepsis: A Randomized Controlled Porcine Study / $c J. Horak, L. Nalos, V. Martinkova, V. Tegl, L. Vistejnova, J. Kuncova, M. Kohoutova, D. Jarkovska, M. Dolejsova, J. Benes, M. Stengl, M. Matejovic
520    9_
$a Background: Treatment with mesenchymal stem cells (MSCs) has elicited considerable interest as an adjunctive therapy in sepsis. However, the encouraging effects of experiments with MSC in rodents have not been adequately studied in large-animal models with better relevance to human sepsis. Objectives: Here, we aimed to assess safety and efficacy of bone marrow-derived MSCs in a clinically relevant porcine model of progressive peritonitis-induced sepsis. Methods: Thirty-two anesthetized, mechanically ventilated, and instrumented pigs were randomly assigned into four groups (n = 8 per group): (1) sham-operated group (CONTROL); (2) sham-operated group treated with MSCs (MSC-CONTROL); (3) sepsis group with standard supportive care (SEPSIS); and (4) sepsis group treated with MSCs (MSC-SEPSIS). Peritoneal sepsis was induced by inoculating cultivated autologous feces. MSCs (1 × 106/kg) were administered intravenously at 6 h after sepsis induction. Results: Before, 12, 18, and 24 h after the induction of peritonitis, we measured systemic, regional, and microvascular hemodynamics, multiple-organ functions, mitochondrial energy metabolism, systemic immune-inflammatory response, and oxidative stress. Administration of MSCs in the MSC-CONTROL group did not elicit any measurable acute effects. Treatment of septic animals with MSCs failed to mitigate sepsis-induced hemodynamic alterations or the gradual rise in Sepsis-related organ failure assessment scores. MSCs did not confer any protection against sepsis-mediated cellular myocardial depression and mitochondrial dysfunction. MSCs also failed to modulate the deregulated immune-inflammatory response. Conclusion: Intravenous administration of bone marrow-derived MSCs to healthy animals was well-tolerated. However, in this large-animal, clinically relevant peritonitis-induced sepsis model, MSCs were not capable of reversing any of the sepsis-induced disturbances in multiple biological, organ, and cellular systems.
650    _2
$a zvířata $7 D000818
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a transplantace mezenchymálních kmenových buněk $x metody $7 D045164
650    _2
$a náhodné rozdělení $7 D011897
650    _2
$a sepse $x terapie $7 D018805
650    _2
$a prasata $7 D013552
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Nalos, Lukas $u Faculty of Medicine in Pilsen, Biomedical Center, Charles University, Pilsen, Czechia $u Department of Physiology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
700    1_
$a Martinkova, Vendula $u Faculty of Medicine in Pilsen, Biomedical Center, Charles University, Pilsen, Czechia $u Third Department of Surgery, University Hospital Motol and First Medical School, Charles University, Prague, Czechia
700    1_
$a Tegl, Vaclav $u Faculty of Medicine in Pilsen, Biomedical Center, Charles University, Pilsen, Czechia $u Department of Anesthesia and Intensive Care Medicine, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
700    1_
$a Vistejnova, Lucie $u Faculty of Medicine in Pilsen, Biomedical Center, Charles University, Pilsen, Czechia $u Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
700    1_
$a Kuncova, Jitka $u Faculty of Medicine in Pilsen, Biomedical Center, Charles University, Pilsen, Czechia $u Department of Physiology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
700    1_
$a Kohoutova, Michaela $u Faculty of Medicine in Pilsen, Biomedical Center, Charles University, Pilsen, Czechia $u Department of Physiology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
700    1_
$a Jarkovska, Dagmar $u Faculty of Medicine in Pilsen, Biomedical Center, Charles University, Pilsen, Czechia $u Department of Physiology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
700    1_
$a Dolejsova, Martina $u Faculty of Medicine in Pilsen, Biomedical Center, Charles University, Pilsen, Czechia
700    1_
$a Benes, Jan $u Faculty of Medicine in Pilsen, Biomedical Center, Charles University, Pilsen, Czechia $u Department of Anesthesia and Intensive Care Medicine, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
700    1_
$a Stengl, Milan $u Faculty of Medicine in Pilsen, Biomedical Center, Charles University, Pilsen, Czechia $u Department of Physiology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
700    1_
$a Matejovic, Martin $u First Medical Department, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia $u Faculty of Medicine in Pilsen, Biomedical Center, Charles University, Pilsen, Czechia
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 11, č. - (2020), s. 126
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32117276 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507102246 $b ABA008
999    __
$a ok $b bmc $g 1651109 $s 1133245
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 11 $c - $d 126 $e 20200207 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Možnosti archivace